Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANTE trial of atezolizumab plus perioperative FLOT versus FLOT alone in resectable gastroesophageal adenocarcinoma
2017-001979-23Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, docetaxel, oxaliplatin, fluorouracil and folinic acid in gastric adenocarcinoma, gastroesophageal adenocarcinoma and esophagogastric junction cancer (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Event-free survival. Started Dec 2017; status: active.
02
Drugs
atezolizumabdocetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on 2017-001979-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001979-23.